Eikon Therapeutics, Inc. Common Stock (EIKN) is a publicly traded the market company. As of May 21, 2026, EIKN trades at $10.79 with a market cap of $636.13M and a P/E ratio of -4.30. EIKN moved +0.19% today. Year to date, EIKN is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $7.90 to $17.40. Analyst consensus is buy with an average price target of $25.20. Rallies surfaces EIKN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Eikon Holds $596M Cash, Boosts R&D 24% on Oncology Pipeline: Eikon ended Q1 2026 with $596 million cash, funding operations into H2 2027, and R&D expenses climbed 24% to $70 million, including a $5 million milestone payment. Three lead oncology programs—EIK1001, EIK1003 and EIK1005—advanced into Phase2/3 trials with six ASCO abstracts accepted in NSCLC, melanoma, ovarian and breast cancer.
| Metric | Value |
|---|---|
| Price | $10.79 |
| Market Cap | $636.13M |
| P/E Ratio | -4.30 |
| EPS | $-2.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.40 |
| 52-Week Low | $7.90 |
| Volume | 2.91K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.38M |
| Net Income | $-82.96M |
| Gross Margin | 0.00% |
5 analysts cover EIKN: 0 strong buy, 4 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.20.